Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Merck & Co Inc and Prometheus Biosciences Inc said that they had entered into a definitive agreement under which Merck, through a subsidiary, will acquire Prometheus for $200.00 per share in a $10.8 billion all-cash deal.

Prometheus is a clinical-stage biotechnology firm pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

Prometheus is developing PRA023 for the treatment of immune-mediated diseases such as ulcerative colitis, Crohn’s disease as well as other autoimmune conditions.

“This agreement with Merck, a leader in biopharmaceutical research and development, allows Prometheus to maximize the potential for PRA023, while continuing to apply our technology and expertise to fuel further discoveries to address the needs of patients with immune disorders,” Mark McKenna, Chairman and Chief Executive Officer of Prometheus Biosciences, said in a press release.

“By applying a portfolio of powerful analytic tools to a comprehensive collection of IBD samples, Prometheus identified important disease insights that have now yielded a promising late-stage candidate,” Dean Y. Li, President, Merck Research Laboratories, said.

The deal is expected to be finalized during the third quarter of 2023.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Oil prices hold steady ahead of FOMC meeting conclusion, API data supportsOil prices hold steady ahead of FOMC meeting conclusion, API data supports Both West Texas Intermediate and Brent benchmarks posted minor advances on Wednesday after the American Petroleum Institute reported a third consecutive weekly decline in US crude inventories, while gasoline and distillate fuel inventories […]
  • New Zealand’s trade surplus highest since May 2020New Zealand’s trade surplus highest since May 2020 New Zealand's trade surplus has expanded to $699 million in June, data by Statistics New Zealand showed, from $204 million in May.The figure outstripped market consensus of $294 million and pointed to the highest trade surplus since […]
  • BG Group Plc announces expectations of lower 2013 earningsBG Group Plc announces expectations of lower 2013 earnings BG Group Plc became the second oil and gas producer to issue a profit warning this month. The company, which operates as an integrated natural gas company and explores, develops, produces liquefies and markets hydrocarbons with a focus on […]
  • Gold touches nine-week highs amid increased haven’s demandGold touches nine-week highs amid increased haven’s demand Gold advanced to the highest level in more than two months, after a slump in equities on concern that growth in emerging economies will slow, boosted demand for the yellow metal as an alternative investment. A weaker dollar and increased […]
  • AUD/USD extended gains from yesterdayAUD/USD extended gains from yesterday Australian dollar continued to advance against its US peer on Tuesday after the Australian elections and another set of upbeat Chinese data.AUD/USD touched a session high at 0.9288 at 5:31 GMT, the pairs highest point since July. Support […]
  • USD/CAD confined in tight range ahead of FOMC, Canada CPIUSD/CAD confined in tight range ahead of FOMC, Canada CPI The USD/CAD currency pair traded within a narrow range on Tuesday ahead of the outcome of the Federal Reserve's two-day policy meeting and Canada's CPI data.Markets are now pricing in about a 67% chance of a 50 basis point Fed rate cut […]